Share Name Share Symbol Market Type Share ISIN Share Description
Omega Dia LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.25p +1.09% 23.125p 23.00p 23.25p 23.125p 22.875p 22.875p 24,266 08:16:46
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 14.2 0.7 1.1 21.0 29.36

Omega Diagnostics Share Discussion Threads

Showing 2001 to 2024 of 2025 messages
Chat Pages: 81  80  79  78  77  76  75  74  73  72  71  70  Older
DateSubjectAuthorDiscuss
21/9/2017
08:34
Yep, the finals noted that Q1 trading had been nicely in line with expectations, and hopefully the company will have timed the fundraising in order to reward investors with positive news flow soon on CD4, Allersys etc.
rivaldo
19/9/2017
11:04
I take it we have approx. 4 weeks until our next schedule trading update, mid October last year....should be lots of progress since the last update!!
barrywhit
16/9/2017
13:25
p1nkfish - chart observation is one I made on lse yday. Positive.
dibs61
15/9/2017
21:17
Delayed trades are very annoying, almost unfair. Chart looks perky though, ready to move.
p1nkfish
15/9/2017
19:29
Large delayed trades showing from Wed. & Thursday.....
barrywhit
14/9/2017
07:44
No worries. It's the only product of its kind at this stage of development and it is exactly what is required for the great need in POC treatment. It will surely transform ODX's sales in future years and could/should take a dominant place in the market. This is not to mention all of ODX's other initiatives. I think we'll be bought out eventually
dibs61
13/9/2017
19:01
Thanks for posting the Unicef POC comparison sheets Dibs. They clearly show Visitect CD4 as the only device that never needs a power source. I'm sure WHO will be eager to see it rolled out in poor countries.
columbarius
13/9/2017
14:04
Longshanks - yes that's what my research has now revealed. It thus requires a power supply (unlike Visitect). I also noticed it appears to require temp storage between 2-30C and has other limitations. Assuming Visitect CD4 receives CE marking before end this year I believe it will also require a 'prerequisite' from the WHO. Once we have that it's lift off with progressively growing sales
dibs61
13/9/2017
13:54
Can someone plz sell so that i buy.
jeevsje
13/9/2017
13:51
Dibs I believe the Alere device is a machine rather than a comparable POC device to Visitect
longshanks
13/9/2017
13:50
I am bipolar.
jeevsje
13/9/2017
13:43
Jeevsje you posted this not too long ago"Omega is going down, down, down. That 40k sell was well below bid and they were not accepting my sale order yesterday. Can you please buy so that I can sell?"I hope you take this opportunity to sell to save yourself and us your ongoing anguish
longshanks
13/9/2017
13:19
Chart starting to look good.
jeevsje
13/9/2017
12:39
And up we go :)
dibs61
13/9/2017
12:17
A couple of buys going through at well above quoted ask @ 23.5 Incidentally does anybody know if the Alere Pima CD4 POC is a direct competitor to Visitect CD4?
dibs61
12/9/2017
18:03
Another new position is being advertised on twitter. Senior scientist
longshanks
11/9/2017
14:17
It's a bold man who makes a prediction about a product he doesn't understand.
columbarius
10/9/2017
17:57
Bye bye buywellI hope you find a glass half full somewhere some time
longshanks
09/9/2017
14:42
I predict CD4 will be a waste of money but lucky for you guys ... I take my leave Last post from me I will only return if this hits 13p dyor always
buywell3
09/9/2017
13:39
Good support last week all sells picked up, we seem to have buyers at 22p..........
barrywhit
07/9/2017
15:43
Not much satisfaction in beating someone either too dim or too lazy to find out for themselves.
columbarius
07/9/2017
15:16
Strike one
longshanks
07/9/2017
14:53
Good support for the stock even without any updates.....bodes well....GLA
barrywhit
07/9/2017
13:48
Global guidelines continue to be updated as evidence on best practice in caring for and treating people living with HIV is gathered. CD4 testing is one of the steps taken to initiate people living with HIV/AIDS onto ART and is an effective tool in determining the immunological status of patients, in prioritising patients at risk of Opportunistic Infections and in prioritising patients for initiating ART where Treat All is still not a realistic option.
barrywhit
Chat Pages: 81  80  79  78  77  76  75  74  73  72  71  70  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20170921 10:41:12